help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pietschmann, P.
Right arrow Articles by Smolen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pietschmann, P.
Right arrow Articles by Smolen, J.

Journal of Clinical Endocrinology & Metabolism, Vol 66, 1071-1074, Copyright © 1988 by Endocrine Society

ARTICLES

Decreased serum osteocalcin levels in phenprocoumon-treated patients

P Pietschmann, W Woloszczuk, S Panzer, P Kyrle and J Smolen
Department of Internal Medicine II, University of Vienna, Austria.

Osteocalcin (OC) is a noncollagenous bone matrix protein containing gamma-carboxyglutamic acid, the synthesis of which is vitamin K dependent. Serum OC levels are generally believed to reflect the de novo synthesis of OC by osteoblasts and thus reflect bone formation. We measured serum OC levels by RIA in 48 patients receiving phenprocoumon anticoagulant treatment, which inhibits the posttranscriptional synthesis of gamma-carboxyglutamic acid, and in 22 matched normal subjects. The median serum OC level in the patients receiving phenprocoumon therapy was significantly lower than that in the normal subjects (P less than 0.0001). In 27 patients receiving anticoagulant therapy and in 21 normal subjects the proportion of noncarboxylated OC to total OC also was determined. The proportion of OC that was noncarboxylated was significantly higher in the patients receiving phenprocoumon therapy than in the normal subjects (P less than 0.0001). We conclude that OC carboxylation is impaired in patients receiving oral anticoagulant therapy. The decreased total OC levels in patients receiving phenprocoumon treatment might result from decreased bone formation, although these patients do not have symptoms of bone disease.


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
S. L Booth, A. H Lichtenstein, M. O'Brien-Morse, N. M McKeown, R. J Wood, E. Saltzman, and C. M Gundberg
Effects of a hydrogenated form of vitamin K on bone formation and resorption
Am. J. Clinical Nutrition, December 1, 2001; 74(6): 783 - 790.
[Abstract] [Full Text]

Home page
 Am. J. Clin. Nutr.Home page
N. C Binkley, D. C Krueger, J. A Engelke, A. L Foley, and J. W Suttie
Vitamin K supplementation reduces serum concentrations of under-{gamma}-carboxylated osteocalcin in healthy young and elderly adults
Am. J. Clinical Nutrition, December 1, 2000; 72(6): 1523 - 1528.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society